



UMC Utrecht

## **Eurocor Dior-DEB**

### **“Some Basics”**

Pieter R. Stella, MD, PhD  
Dept. of Interventional Cardiology  
University Medical Centre Utrecht  
The Netherlands  
[p.stella@umcutrecht.nl](mailto:p.stella@umcutrecht.nl)



UMC Utrecht

## **Disclosure Statement of Financial Interest**

*Member Advisory Board Eurocor GmbH*

# Potential Advantages DEB

1. Homogeneous local drug delivery over very short period of time :  
Drug concentrations at vessel wall highest at time of injury
2. Afterwards : absence of drug helps re-endothelialization : reduce dual antiplatelet therapy
3. Avoid chronic inflammation due to absence off polymers
4. Absence of a stent allows for preservation of the original vessel anatomy  
(Bifurcations, small diffuse disease)
5. Avoid double/triple metal layers in case of ISR or BIF
6. Easy lesion crossing / deliverability by balloon only (small vessels)
7. No stent fractures ( BTK )

# Baseline Messages

1. Not every DEB is the same ! Different coatings and concentrations may lead to different tissue concentrations!
2. We need to establish the ideal tissue concentration and need to know per product / manufacturer
3. At TCT 2010 there will be additional presentations on :
  - Dior Clinical Programme : 2.31 @ Ballroom C
  - Valvuloplasty – Dr. Spargias : 2.34 @ 145 A/B

And a last remark:

we call a Drug Eluting Stent : DES

why call a Drug Eluting Balloon : DCB ??

“Back to the Future” with **DEB !**

